Seneca Therapeutics, Inc (STI)
STI is developing Seneca Valley Virus, a cancer immunotherapy. After reactivating the IND STI will start PH 2 studies including orphan and high-need indications
Seneca Therapeutics' oncolytic immunotherapeutic (Seneca Valley Virus, SVV) has proven human safety and indications of efficacy in solid cancer clinical trials. STI is preparing to reactivate an existing IND and initiate Phase II clinical trials to demonstrate a 2-3X increased response rate for checkpoint inhibitors in high-need indications. SVV has significant advantages over competitors. STI is targeting a high multiple exit with this data.